Yes I agree in principle. I hold some other companies in the same sector and none have a SP near IPD without already having revenue and positive cashflow to justify it, thats where I'm coming from
- Forums
- ASX - By Stock
- IPD
- Ann: US FDA 510(k) Clearance for Bilateral Lymphoedema Assessment
IPD
impedimed limited
Add to My Watchlist
8.33%
!
0.6¢
Ann: US FDA 510(k) Clearance for Bilateral Lymphoedema Assessment, page-5
-
-
Top Stories
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
